Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why? -- Ignore unavailable to you. Want to Upgrade?

To: Douglas who wrote (443)	8/15/1999 3:10:00 PM
From: Douglas	Respond to of 455

Insider Buying (Good news & very small float!) 08/12/1999 Federal Filings Newswires FFBN SOURCE: FORM4 ISSUER: PROCEPT INC. SYMBOL: PRCT FILER: ARIES DOMESTIC FUND LP TITLE: Beneficial Owner TRANSACTION: Purchase 3,451 07/06/1999-07/23/1999 1.46-1.75 OWNERSHIP: 3,090,492 FILER: ARIES MASTER FUND TITLE: Beneficial Owner TRANSACTION: Purchase 5,162 07/23/1999 1.46 OWNERSHIP: 6,137,612

To: Douglas who wrote (443)	8/15/1999 3:12:00 PM
From: Douglas	Read Replies (1) \| Respond to of 455

From 2nd Quarter Announcement: ``We are making substantial progress in implementing Procept's clinical development strategy,' said John F. Dee, President and Chief Executive Officer of Procept, Inc. ``The initiation of additional clinical trials for PRO 2000 Gel and O6-Benzylguanine is imminent. With the current government support and funding, the Company should continue to advance its clinical development and improve the potential for securing corporate partnerships.'